Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults

Crum-Cianflone, Nancy F.; Iverson, Erik; Defang, Gabriel; Blair, Patrick J.; Eberly, Lynn E.; Maguire, Jason D.; Ganesan, Anuradha; Faix, Dennis J.; Duplessis, Christopher; Lalani, Tahaniyat; Whitman, Timothy J.; Brandt, Carolyn; Macalino, Grace; Millar, Eugene V.; Burgess, Timothy

doi:10.1016/j.vaccine.2011.02.040

Cited by 46 publications

(36 citation statements)

References 43 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite these limitations, our results are in large agreement with data of previous studies based on similar serological methods although most of these studies have assessed post-vaccination HI titers after 1 or 3 months [9,26,30,31]. Thus, weaning of antibody titers that was previously shown to be accelerated in immunosuppressed patients [32] seems not to be the major limitation of this study. Since European inXuenza season lasts about 4.5 months [33], a durable antibody response is desirable.…”

Section: Discussionsupporting

confidence: 89%

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients

Ott

Sauerbrei

Lange

et al. 2012

Med Microbiol Immunol

View full text Add to dashboard Cite

In the present study, antibody response to seasonal influenza vaccination and to the adjuvanted one-shot influenza A H1N1 vaccine (Pandemrix(®)) was investigated in 57 hemodialysis (HD) patients and 48 renal transplant (RT) recipients. Specific antibodies were measured by hemagglutination inhibition (HI) test using a pandemic H1N1 strain and a seasonal H3N2 virus. HI titers of ≥1:40 were considered as protective. Hemodialysis patients showed seroprotection against pandemic H1N1 in 35.1%, against seasonal influenza in 36.8% and against both in 14.0%. In comparison, renal transplant recipients developed protective antibody titers against the pandemic H1N1 virus in 47.9%, against the seasonal H3N2 strain in 31.3% and against both in 18.8%. HD patients and renal transplant recipients younger than 60 years developed protective antibody response to the pandemic influenza H1N1 vaccine in 50.0% of the HD patients and 55.2% of the RT recipients and against seasonal influenza in 45.0/20.7% (HD/RT) of the cases. Patients aged ≥60 years showed seroprotection against pandemic influenza in 27.0/36.8% (HD/RT) and against seasonal influenza in 32.4/47.4% (HD/RT). Side effects were reported in only four patients. In hemodialysis patients and renal transplant recipients, vaccination against pandemic H1N1 and seasonal influenza is well tolerated. However, more than a half of these patients did not develop seroprotective antibody levels. Thus, new vaccines and altered vaccination regimes are likely necessary to achieve relevant antibody levels in these patient groups.

show abstract

Section: Discussionsupporting

confidence: 89%

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients

Ott

Sauerbrei

Lange

et al. 2012

Med Microbiol Immunol

View full text Add to dashboard Cite

show abstract

“…[265] Studies on the performance of monovalent inactivated influenza A(H1N1)pdm vaccine have similar findings with reduced immunogenicity (60%) among HIVpositive individuals, particularly those with lower CD4 counts. [267,268] These findings of reduced immunogenicity extend to adjuvanted vaccines (AS03 and MF-59) among HIV-positive compared to HIV-negative individuals. [269][270][271] Two systematic reviews conducted on the effectiveness of influenza vaccines among HIV-positive populations showed limited evidence of VE in this population and called for more data from RCT settings.…”

Section: Disease Burdenmentioning

confidence: 80%

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

Rondy¹,

Launay

Puig-Barberà

et al. 2015

Eurosurveillance

View full text Add to dashboard Cite

show abstract

“…6 Similarly, 87% seroprotection was reported at 6 mo in a clinical trial involving 53 adults. 7 However, only 35.1% vaccinees had seroprotection at 9 mo in a field evaluation in China. 8 Similarly, only 34% of 86 vaccinees had seroprotection at 6 mo in China.…”

mentioning

confidence: 99%

Antibody persistence after Pandemic H1N1 2009 influenza vaccination among healthcare workers in Pune, India

Tandale

Pawar²,

Gurav³

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults

Cited by 46 publications

References 43 publications

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients

Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

Antibody persistence after Pandemic H1N1 2009 influenza vaccination among healthcare workers in Pune, India

Contact Info

Product

Resources

About